Department of Otorhinolaryngology, Ufuk University Medical School, and ENT Department, Ankara Training and Research Hospital, Ankara, Turkey.
Med Sci Monit. 2012 Apr;18(4):BR135-43. doi: 10.12659/msm.882615.
In recent years, pimecrolimus 1% cream has been demonstrated to reduce symptoms of atopic dermatitis in patients when applied topically.
MATERIAL/METHODS: In our study we compared the therapeutic effects of local 1% pimecrolimus to 1% hydrocortisone, and to a control group in a mouse model with atopic dermatitis in the external ear canals. Atopic dermatitis was created by application of Dinitrochlorobenzene in the external ear canals of mice. The development of atopic dermatitis was detected by clinical observation score and determination of total serum IgE levels. Pimecrolimus and hydrocortisone cream were topically applied to the external ear canal skin once a day for 14 days.
There was no significant difference between the hydrocortisone and the pimecrolimus therapy groups, while there was a statistically significant difference between these 2 groups and the control group (p<0.05) Assessment of the clinical observation scoring carried out on the 14th day of therapy revealed that there was no difference between the hydrocortisone and pimecrolimus groups. Biopsies were taken on the 14th day following treatment. Tissue samples were histologically evaluated; contact dermatitis was observed microscopically in the control group, but in the therapy groups only minimal evidence of contact dermatitis was found.
The results of our study reveal that the therapeutic efficacy of 1% pimecrolimus was equivalent to 1% hydrocortisone treatment in the artificially developed atopic dermatitis model in external ear canals of mice. These results clearly demonstrate that 1% pimecrolimus cream can be an effective alternative therapeutic agent in cases where steroid treatment proves to be insufficient or in cases where treatment must be discontinued due to its adverse effects.
近年来，吡美莫司 1%乳膏已被证明可通过局部应用减轻特应性皮炎患者的症状。
材料/方法：在我们的研究中，我们比较了局部 1%吡美莫司与 1%氢化可的松以及对照组在患有特应性皮炎的小鼠外耳道模型中的治疗效果。通过在外耳道涂抹二硝基氯苯来创建特应性皮炎。通过临床观察评分和总血清 IgE 水平的测定来检测特应性皮炎的发展。吡美莫司和氢化可的松乳膏每天在外耳道皮肤局部涂抹一次，共 14 天。
氢化可的松和吡美莫司治疗组之间没有显著差异，而这两组与对照组之间有统计学差异（p<0.05）。在第 14 天治疗时进行的临床观察评分评估显示，氢化可的松和吡美莫司组之间没有差异。在治疗后第 14 天进行活检。组织样本进行组织学评估；对照组观察到接触性皮炎，而在治疗组仅发现轻微的接触性皮炎证据。
我们的研究结果表明，1%吡美莫司的治疗效果等同于 1%氢化可的松在小鼠外耳道人工诱导的特应性皮炎模型中的治疗效果。这些结果清楚地表明，1%吡美莫司乳膏可作为治疗特应性皮炎的有效替代药物，在需要类固醇治疗但效果不足或因副作用而需要停药的情况下尤其适用。
